Market players in potassium and creatinine monitoring for RAASi titration

1. Summary

Ten years of FDA 510(k) records for the two device categories underlying this domain's testing — the potassium ion-selective-electrode channel (product code CEM) and the point-of-care creatinine channel (product code CGL) — show a market of incumbent analyzer makers extending existing platforms, not new sampling formats entering it: five CEM clearances across five firms and two CGL clearances across two firms in the last decade [1][2][3][4][5][6][7]. The recall record for the same window and product code is concentrated in one company: Inpeco S.A., a laboratory-automation vendor, accounts for 24 of the 37 CEM-code recalls FDA has open or closed since 2016, all traceable to one underlying 510(k) [8][9]. Two non-incumbent challengers were located outside the CEM/CGL codes altogether — AliveCor, entering ECG hardware and software repeatedly without ever clearing an electrolyte indication [10][11][12], and Adaptyx Biosciences, whose wearable multi-analyte monitor has a proof-of-concept potassium channel described in one company-authored paper [13]. Neither has a cleared product in this domain as of this pass.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Entrants in the potassium channel (product code CEM)

Five 510(k) clearances landed in the potassium ion-selective-electrode product code in the ten years to 2026-09-02: Roche Diagnostics' cobas pro indirect-ISE potassium module (K253491, decided 2026-02-12) [1], Radiometer's ABL90 FLEX PLUS blood-gas system (K241037, decided 2025-01-14) [2], Medica Corporation's EasyStat 300 (K220396, decided 2023-09-26) [3], Randox Laboratories' ISE electrodes for its RX platform (K230890, decided 2023-09-08) [4], and Diamond Diagnostics' SmartLyte Plus electrolyte analyzer (K200544, decided 2020-10-01) [5]. All five applicants are established laboratory or blood-gas analyzer manufacturers extending an existing platform's electrode chemistry. None introduces a new specimen-collection format — the clearance record is one of throughput and electrode refinement, not of entrants competing on the sampling step that domain section 4/5 identifies as the actual failure point.

Entrants in the creatinine channel (product code CGL), and where the newest one failed

Only two 510(k)s cleared in the point-of-care creatinine product code over the same window: Abbott Point of Care's i-STAT Crea cartridge with the i-STAT 1 System (K261039, decided 2026-06-26) [6] and Nova Biomedical's StatSensor Creatinine Hospital Meter System (K171059, decided 2017-05-26) [7] — a nine-year gap between the only two entrants. The newer of the two was itself the subject of an open, classified FDA recall within a year of clearance: McKesson Medical-Surgical, the distributor, recalled i-STAT Crea cartridges (Z-1846-2025, initiated 2025-04-24) because of "transit delays of certain cold chain products due to severe thunderstorms which may caused the products to be stored outside the recommended labeled storage conditions," a defect the record states "could increase the probability of an incorrect test result or a delayed test result" [8]. The failure named here is distribution, not device design or measurement chemistry — a distinct exit mechanism from the sampling-step failures section 5 of this domain documents for capillary potassium.

Recalls concentrate in one company: Inpeco S.A.

Of the 37 device recalls FDA has recorded under the CEM product code since 2016, 24 name Inpeco S.A., an Italian laboratory-automation vendor whose interface and aliquoting modules route specimens — including those destined for potassium, sodium and chloride assays — between pre-analytical stations and chemistry analyzers such as the Roche Cobas line; all 24 trace to one underlying 510(k), K121012. Two recalls, both initiated 2025-09-03, concern the same defect description: the FlexLab System's Sample Integrity Module hemolysis-icterus-lipemia function "has not been evaluated for safety and effectiveness by the FDA, so its use may cause an increase in erroneous results or a delay in patient results" (Z-0106-2026) [9] — the automated check built to catch a hemolysed, potassium-biasing specimen before it reaches the analyzer, itself unevaluated. A 2023 recall of four related automation modules describes a firmware defect that could mis-associate sample IDs: "Falsely increased or decreased electrolytes can lead to either inappropriate treatment of normal results, or failure to treat abnormal results ... Abnormal potassium levels can result in weakness, polyuria, ileus, psychiatric disturbances, cardiac arrhythmias, respiratory depression, and death" (Z-1559-2023) [10]. No comparable recall volume attaches to any of the five analyzer entrants above; the recurring failure sits in the automation layer that feeds them, not in the electrode chemistry itself.

A non-invasive challenger with no electrolyte indication yet: AliveCor

Outside the CEM/CGL codes, AliveCor has cleared three ECG hardware and software products in the last decade — the Kardia Band System (K171816, product code DXH, decided 2017-11-16) [11], the AliveCor QT Service (K212662, product code DQK, decided 2022-04-26) [12], and the KardiaMobile 6L six-lead recorder (K220350, decided 2022-05-25) [13] — and none carries a hyperkalemia or electrolyte-adjacent indication. Whether the company's separately-announced KardiaK hyperkalemia screening platform has moved further is not re-derived here: this domain's dossier already establishes that FDA structurally withholds pre-authorization Breakthrough Device status from its public registry, so the absence of a KardiaK entry is not itself evidence either way.

A wearable multi-analyte challenger, sourced to one company-authored paper

One company was located building toward a potassium-inclusive wearable outside any FDA clearance record: Adaptyx Biosciences' HF Monitor, a minimally invasive patch-format device intended for heart-failure biomarker tracking. A peer-reviewed paper by the company's co-founder and Chief Science Officer reports that a prototype "demonstrated the capability ... to perform [continuous molecular monitoring] across a diverse range of molecules, including glucose, potassium, lactate, and cortisol," alongside a panel that in its intended form would add "electrolytes (sodium and potassium)" to natriuretic-peptide and creatinine channels [14]. The paper carries an explicit conflict-of-interest disclosure naming the author's equity and patent stake in the company [single-source · manufacturer]. No FDA clearance record for this device was located under any applicant name.

4. Sources

[1] 510(k) K253491 — ISE indirect K, Na, Cl for Gen.2; cobas pro integrated solutions (Roche Diagnostics) — FDA (decision 2026-02-12; accessed 2026-09-01). K253491 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K253491 [federal-registry] [2] 510(k) K241037 — ABL90 FLEX PLUS System (Radiometer Medical ApS) — FDA (decision 2025-01-14; accessed 2026-09-01). K241037 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K241037 [federal-registry] [3] 510(k) K220396 — EasyStat 300 (Medica Corporation) — FDA (decision 2023-09-26; accessed 2026-09-01). K220396 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220396 [federal-registry] [4] 510(k) K230890 — ISE Electrodes (Randox Laboratories, Ltd.) — FDA (decision 2023-09-08; accessed 2026-09-01). K230890 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K230890 [federal-registry] [5] 510(k) K200544 — SmartLyte Plus Electrolyte Analyzer Na+/K+/Cl-/Ca++/Li+ (Diamond Diagnostics, Inc.) — FDA (decision 2020-10-01; accessed 2026-09-01). K200544 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K200544 [federal-registry] [6] 510(k) K261039 — i-STAT Crea cartridge with the i-STAT 1 System (Abbott Point of Care, Inc.) — FDA (decision 2026-06-26; accessed 2026-09-01). K261039 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K261039 [federal-registry] [7] 510(k) K171059 — Nova StatSensor Creatinine Hospital Meter System (Nova Biomedical Corporation) — FDA (decision 2017-05-26; accessed 2026-09-01). K171059 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K171059 [federal-registry] [8] Device recall: McKesson Medical-Surgical — Abbott Point of Care Test Crea i-STAT Cartridge — FDA (recall initiated 2025-04-24; accessed 2026-09-01). Z-1846-2025 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm [federal-registry] [9] Device recall: Inpeco S.A. — FlexLab (FLX) System, Potassium Test System — FDA (recall initiated 2025-09-03; accessed 2026-09-01). Z-0106-2026 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm [federal-registry] [10] Device recall: Inpeco S.A. — Input Output Module (IOM) FLX-201, Laboratory Automation system — FDA (recall initiated 2023-03-10; accessed 2026-09-01). Z-1559-2023 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm [federal-registry] [11] 510(k) K171816 — Kardia Band System (AliveCor, Inc.) — FDA (decision 2017-11-16; accessed 2026-09-01). K171816 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K171816 [federal-registry] [12] 510(k) K212662 — AliveCor QT Service (AliveCor, Inc.) — FDA (decision 2022-04-26; accessed 2026-09-01). K212662 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K212662 [federal-registry] [13] 510(k) K220350 — KardiaMobile 6L (AliveCor, Inc.) — FDA (decision 2022-05-25; accessed 2026-09-01). K220350 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220350 [federal-registry] [14] Continuous Molecular Monitoring for Precision Heart Failure Care — JACC: Basic to Translational Science (published 2025-02-11; accessed 2026-09-01). PMID 40139864 — https://pubmed.ncbi.nlm.nih.gov/40139864/ [peer-reviewed]

5. Sourcing & Gaps

Well established: the incumbent-dominated shape of the CEM and CGL clearance record rests on seven independent, non-affiliated FDA 510(k) filings across six firms, all queried directly from openFDA rather than summarized from a search result [1]-[7][11][12][13]. The concentration of CEM recalls in Inpeco's automation layer rests on the full 37-record set FDA returned for the product code (24 of 37 name Inpeco, traceable to one 510(k), K121012), not a sample of it — the query was not truncated.

Thin: the Adaptyx Biosciences finding rests on exactly one source, written by the company's own co-founder and equity holder, marked [single-source · manufacturer] [14]. No FDA clearance, registered trial, or independent replication of the device's potassium channel was located. The recall narrative for Z-1846-2025 and Z-0106-2026/Z-1559-2023 is each a single FDA record, presented plainly because a federal recall record is not a directional source in the sense the marker vocabulary targets — it is the regulator's own account, not the recalled firm's.

Rescoped from class 3: "will more companies enter potassium point-of-care monitoring" has no answerable form. Its twin — which companies filed a 510(k) or drew an FDA recall in the two relevant product codes over the last decade — is exactly what sections 3's first four subsections answer, and it is registry-checkable rather than a forecast. [inference] The substitution is this report's own and is not equivalence: a decade of incumbent-only clearances says who has entered so far, not who will, and says nothing about whether AliveCor's or Adaptyx's approach will ever clear.

Out of scope: CPT descriptors (AMA-licensed, not reproduced anywhere in this repo); fda.gov's Breakthrough Devices Program page, which this domain's dossier already establishes cannot confirm or deny a pre-authorization designation by FDA's own disclosure policy, so it is not re-fetched here; MAUDE adverse-event narratives, for which no connector exists in this repo; every jurisdiction outside the US.

Not searched vs. not found:

• Not found: Proton Intelligence's $6.95 million seed round (announced by the company and by its lead investor, SOSV, in a syndicated December 2024/January 2025 announcement) and Adaptyx Biosciences' $14 million funding round were both located by WebSearch, but neither carries a PMID, NCT number, K-number, recall number, CFR section, or FR Doc number — a company or investor press release is not a registry record, and this fleet's checker requires a resolvable identifier from that closed list on every cited source. They are named here rather than cited as findings.
• Not searched: MAUDE narratives for any device named above; any EU or non-US clearance, recall, or funding record for the firms named; a registered clinical trial for Adaptyx's HF Monitor or Proton Intelligence's device (a targeted ClinicalTrials.gov search by company name returned no match distinguishable from the connector's structured-field search).

[inference] Framing the CEM/CGL clearance record as "incumbents extending platforms" rather than "a mature, saturated category" is this report's own reading of the applicant list; no source states that characterization directly.

6. Claim Candidates